Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line.

Trial Profile

Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms REMARC
  • Most Recent Events

    • 04 Dec 2018 Results assessing the Impact of Total Metabolic Tumor Volume at Baseline (n=228) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Aug 2018 Planned End Date changed from 1 Sep 2019 to 30 Sep 2019.
    • 20 Apr 2017 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top